PrEP

As investigators continue to study the use of drugs such as remdesivir for the treatment of the COVID-19 pandemic, some researchers are considering drug repurposing as a temporary solution.

Pharmacists push against state-level limits on dispensing of hydroxychloroquine for coronavirus disease 2019.

The FDA has announced that it is accelerating the development of potentially safe and effective life-saving treatments for patients with the coronavirus 2019 disease.

The prevalence of HIV in jails and prisons is approximately 4 times higher than that of the general United States population.

Other therapeutic possibilities include a combination of HIV-1 protease inhibitors.

Researchers at the National Institutes of Health (NIH) have found that the antiretroviral drugs, dolutegravir and emtricitabine/tenofovir alafenamide fumurate (DTG+FTC/TAF), may comprise the safest and most effective HIV treatment regimen currently available during pregnancy.

Recent estimates indicate that less than 10% of patients who are at risk for acquiring HIV are prescribed PrEP.

Levels of the HIV pre-exposure prophylaxis (PrEP) drug tenofovir among African adolescent girls and young women were more than 30% lower in those who were pregnant than in those who had recently given birth.

The US Pharmacopeia (USP) is providing free technical assistance to developers of antiviral drugs and vaccines that will support the public health response to the coronavirus disease 2019 (COVID-19) pandemic.

Only 15% of those at risk are currently using PrEP.

A 72-week interim analysis of observational data from the ongoing SEARCH study was used to examine optimal strategies for PrEP engagement and uptake after population-level HIV testing and universal PrEP access.

Top news from across the health care landscape.

Scientists at the Gladstone Institutes have cataloged host proteins that physically bind to HIV proteins, which identify human proteins that the virus can use to infect cells and spread.

The bill is intended to "prevent a health insurance carrier from requiring a covered person to undergo step therapy or to receive prior authorization before receiving HIV infection prevention drugs."

The Undectectable = Untransmittable (U=U) campaign started in early 2016 and has been sharing the message to dismantle the stigma surrounding HIV ever since. More than 970 community partners from 101 countries have come together to clear up the confusion about the science behind U=U.

Research conducted by the National Institute of Minority Health and Health Disparities has found that less than 1 in 4 adolescent men who have sex with men (AMSM) ever get tested for HIV.

The study, called DELIVER: A Phase 3b Safety Study of the Dapivirine Ring and PrEP in Pregnant Women, will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first 6 months after birth.

A study funded by the National Institutes of Health (NIH) found that despite similar rates of enrollment into medical care, youth with HIV have much lower rates of viral suppression compared with adults.

Researchers from George Washington University have shown that the human apolipoprotein A-I binding protein (AIBP) is capable of inhibiting HIV replication by targeting lipid rafts and reducing virus-cell fusion.

Decreased PrEP usage was reportedly due to reduced awareness of prevention strategies, and engagement in health-promoting behaviors.

Top news from across the health care landscape.

A study found that an injection of neutralizing antibodies is associated with enhanced T cell response that specifically recognizes HIV.

The mechanism behind HIV resistance affects the ability of integrase strand transfer inhibitors to bind and block the HIV enzyme integrase.

Top news of the day from across the health care landscape.

Robust data show the efficacy of tenofovir disoproxil fumarate with emtricitabine for pre-exposure prophylaxis in all priority populations with a risk for HIV.

Opioid agonist therapy (OAT) must be widely disseminated and increased in Ukraine in order to optimize HIV prevention and treatment goals, according to a recent study published in The Lancet.

Antiretroviral therapy may not be entirely effective in restoring the immune protection resulting from viral infections or childhood vaccines received prior to becoming HIV-positive.

The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.

Hospitalization offers unique opportunities to engage out-of-care individuals with the ultimate goal of improving their HIV outcomes and reducing health disparities.

The app takes the authoritative, evidence-based 2015 World Health Organization pre-exposure prophylaxis guidelines and adapts for a mobile device.